Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

2 days ago

New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEX^TM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and immunosuppressive cells

Mipletamig-driven clinical validation of the CRIS-7-derived CD3 binding domain underpins Aptevo's introduction of new, trispecific CD3-directed anti-cancer molecules

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

3 weeks ago

Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.

Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS-7-derived CD3 portfolio targeting both hematologic and solid tumors

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

3 weeks ago

Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types

CD3 bispecific portfolio now includes three candidates - mipletamig (AML), APVO442 (prostate cancer), and newly added APVO455 - advancing a targeted, tumor-specific strategy uniquely engineered for safety, tumor specificity and clinical impact

Mipletamig, continues to outperform benchmarks, trial enrollment continues

$15.9 million raised in 2Q25, extending cash runway into late 4Q25